Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:physicist
|
gptkbp:activities |
replaces deficient enzyme
|
gptkbp:appointed_by |
intravenous infusion
|
gptkbp:approves |
gptkb:1994
gptkb:FDA with sterile water |
gptkbp:brand |
gptkb:Cerezyme
|
gptkbp:clinical_trial |
Phase III
long-term therapy Gaucher disease studies |
gptkbp:contraindication |
hypersensitivity to imiglucerase
|
gptkbp:developed_by |
gptkb:Genzyme_Corporation
|
gptkbp:dosage_form |
solution for infusion
|
gptkbp:duration |
every 2 weeks
lifelong therapy |
gptkbp:education |
adherence to therapy
recognize side effects |
gptkbp:excretion |
urine
|
gptkbp:formulation |
lyophilized powder
|
https://www.w3.org/2000/01/rdf-schema#label |
imiglucerase
|
gptkbp:indication |
gptkb:physicist
acute type 1 Gaucher disease chronic type 1 Gaucher disease |
gptkbp:ingredients |
glucocerebrosidase
C_12 H_19 N_3 O_9 P |
gptkbp:is_atype_of |
A16 A B02
|
gptkbp:is_monitored_by |
liver function tests
hemoglobin levels spleen size platelet counts |
gptkbp:is_used_for |
treatment of Gaucher's disease
|
gptkbp:manager |
intravenous
|
gptkbp:marketed_as |
gptkb:Cerezyme
|
gptkbp:metabolism |
lysosomal degradation
|
gptkbp:name |
Essential Medicines
|
gptkbp:pharmacokinetics |
half-life of 2-3 hours
|
gptkbp:population |
adults and children
|
gptkbp:provides_information_on |
Gaucher disease management
|
gptkbp:research_focus |
gptkb:healthcare_organization
gptkb:physicist patient outcomes biotechnology advancements long-term safety |
gptkbp:shelf_life |
24 months
|
gptkbp:side_effect |
fatigue
headache nausea abdominal pain allergic reactions fever rash joint pain chills infusion reactions |
gptkbp:storage |
refrigerated
|
gptkbp:type |
recombinant glucocerebrosidase
|
gptkbp:type_of |
57636-09-4
|
gptkbp:bfsParent |
gptkb:Cerezyme
|
gptkbp:bfsLayer |
5
|